Click here to take the survey

Response to Issue 14 Questionnaire  Q. No. Total no of responders Question  Options   No of responders Response  Skipped 1 12 What is the prevalence of SpA? Less than that of RA   6 50%   Similar to that of RA   4 34% Higher than that of RA   1 8% Unknown   1 8% 2 12 Regarding inflammatory back pain, indicate which of the following is true or false. The presence of IBP indicates spinal or sacroiliac inflammation True  10 84%   False  2 16% IBPs only indicates a higher risk of having axial inflammatory arthritis True  9 75%   False  3 25% IBP is no longer considered to be clinically relevant in the assessment of axial SpA True  1 8% 1 False  10 84% Absence of IBP indicates that no further evaluation for axial SpA is warranted True  2 16% 1 False  9 75% 3 12 Regarding CASPAR criteria for classification of PsA, indicate which of the following is true or false? CASPAR criteria can be applied to patients with any joint pain or back pain True  8 66%   False  4 34% The presence of psoriasis or history of psoriasis is a mandatory criterion True  6 50%   False  6 50% Rheumatoid Factor positivity precludes classifying patients with inflammatory arthritis as PsA True  7 58% 1 False  4 34% CASPAR criteria allow classification of patients with inflammatory arthritis but without a personal or family history or current psoriasis as having PsA True  3 25% 1 False  8 66% 4 12 According to the expert, the most effective drug with anti-TNF efficacy is Infliximab   5 42%   Etanercept       Adalimumab   1 8% Golimumab       All drugs are equally effective   6 50% 5 12 Regarding the use of MTX in the management of SpA, indicate which of the following is true or false? MTX is effective for axial symptoms True  1 8%   False  11 92% MTX is effective for peripheral arthritis True  9 75%   False  3 25% MTX is effective for enthesitis True  4 34% 1 False  7 58% Anti-TNF therapy should always be used in combination with MTX  True  2 16% 1 False  9 75%